학술논문

An endometrial stromal sarcoma cell line with the JAZF1/PHF1 chimera
Document Type
Source
Cancer Genetics and Cytogenetics. 185(2):74-77
Subject
Base Sequence
DNA Primers
DNA-Binding Proteins
Endometrial Neoplasms
Female
Humans
Karyotyping
Neoplasm Proteins
Recombinant Fusion Proteins
Reverse Transcriptase Polymerase Chain Reaction
Sarcoma
Stromal Cells
Transcription Factors
Journal Article
Research Support
Non-U.S. Gov't
Medicin och hälsovetenskap
Medicinska och farmaceutiska grundvetenskaper
Medicinsk genetik
Medical and Health Sciences
Basic Medicine
Medical Genetics
Klinisk medicin
Cancer och onkologi
Clinical Medicine
Cancer and Oncology
Language
English
ISSN
0165-4608
Abstract
Endometrial stromal sarcomas (ESS) are rare malignancies, accounting for less than 10% of uterine sarcomas. Apart from the chromosomal rearrangement t(7;17)(p15;q21), which leads to the JAZF1/SUZ12 chimera, cytogenetic studies have shown that the chromosome band 6p21 is often rearranged in ESS. The translocation partners involved in the 6p21 rearrangements differ among the tumors, but chromosome 7 is involved in most aberrations. A JAZF1/PHF1 fusion gene was recently found in two tumors showing an exchange between 6p and 7p rearrangement. In the present study, we show that a low-grade ESS cell line carrying a der(7)t(6;7)(p21;p22) also harbors the a JAZF1/PHF1 fusion. In the fusion transcript, exon 3 of JAZF1 was fused with exon 2 of PHF1. At the junction, there was an insertion of 26 nucleotides, originating from intron 3 of JAZF1, thus maintaining an open reading frame of the chimeric transcript. The predicted 684-amino acid JAZF1/PHF1 chimeric protein retained one zinc finger domain from JAZF1 and the two zinc finger domains from PHF1, and its oncogenic mechanism should be similar to that of the JAZF1/SUZ12 protein. The present cell line constitutes an excellent model for further studies on the impact of the JAZF1/PHF1 fusion.